A new hope for early gonarthrosis treatment using a biotechnological therapeutic drug to regenerate cartilage by intra-articular knee injection

Informazioni relative al progetto

RHYP

ID dell’accordo di sovvenzione: 766606

DOI 10.3030/766606

Progetto chiuso

Data della firma CE 31 Maggio 2017

Data di avvio 1 Giugno 2017

Data di completamento 30 Novembre 2020

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Costo totale € 3 008 500,00

Contributo UE € 2 105 950,00

Coordinato da

REGULAXIS
France

Risultati finali

Documents, reports (4)

Report on volunteers recruitment and clinical trial launch
Copy of CTA folder
Ethical protocols reports and authorization approval copies
Report to present RHYP corporate identity and first leaflet and promotion material models

Pubblicazioni

Peer reviewed articles (1)

REG-O3 chimeric peptide combining growth hormone and somatostatin sequences improves joint function and prevents cartilage degradation in rat model of traumatic knee osteoarthritis

Autori: Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Sébastien Pirson, Thibaut Neutelings, Yves Henrotin, Christelle Vêtu
Pubblicato in: PLOS ONE, Numero 15/4, 2020, Pagina/e e0231240, ISSN 1932-6203
Editore: Public Library of Science
DOI: 10.1371/journal.pone.0231240